Cystine
DrugUsed for smoking cessation and alcohol reduction
NCT Number: NCT06790342
People with HIV (PWH) smoke tobacco cigarettes and drink alcohol at higher rates than the general population, both in the US and internationally, including low- and middle-income countries. Now that effective antiretroviral therapy is available throughout most of the world, PWH are surviving long enough to manifest the lethal consequences of both their smoking and drinking. In this project, the investigational team aims to advance the knowledge and understanding of treatment strategies (i.e. individual intensive counseling ± pharmacotherapy with cytisine) that target both tobacco and alcohol use among PWH in Kenya, a resource constrained environment, and to generate outcome data that may benefit co-users of tobacco and alcohol throughout the world.
Trial opening soon.
Get Notified18 year–80 year
All sexes
Interventional
Phase 3
Mathari National Teaching and Referral Hospital, Nairobi, Kenya
This study was reviewed and approved for data analysis by the University of Chicago.
The research portion of this study was also submitted to and is pending approval from:
Board Name: AMREF ETHICAL AND SCIENTIFIC REVIEW COMMITTEE (ESRC) Board Affiliation: The AMREF ESRC is affiliated with AMREF Health Africa and accredited by National Commission for Science, Technology and Innovation (NACOSTI) since 200 Phone: +254 20 699 4000 Email: [email protected]
Address:
Langata Road PO Box 27691-00506 Nairobi, Kenya
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Used for smoking cessation and alcohol reduction
An 8 session tailored behavioral treatment for smoking cessation and alcohol reduction
Matched to cystine
Standardized brief advice to quit smoking (standard of care)
Time frame: 36 months
Defined as self-reported no smoking in the past 7 days + Carbon Monoxide (CO)<7 ppm
Time frame: 36 months
PEth level of less than 50ng/dl for cessation from heavy drinking linked (P30D)
Time frame: 36 months
denial of self-reported heavy drinking days (denying any prior 7-day period with >7 drinks or any single day with 4 drinks) for the past 30 days
Contact information is provided by the study sponsor or research team.
Emily Koech, MD
CONTACT
Walter Mchembere
CONTACT
University of Chicago
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06004830
Acquired Immunodeficiency Syndrome, Alcohol Use Disorder
Decatur, Georgia, United States
View Trial DetailsNCT05852860
Behavior, Chemically-Induced Disorders
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT05642715
Acquired Immunodeficiency Syndrome, Behavior
The Bronx, New York, United States
View Trial DetailsNCT06006143
Acquired Immunodeficiency Syndrome, Alcohol Use Disorder
Decatur, Georgia, United States
View Trial Details